FORO DE I+D BIOMEDICA GLOBAL LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA: CHINA, SINGAPUR Y COREA DEL SUR STRENGHTS, CHALLENGES AND DRIVERS OF THE CHINESE

EMERGI NGENTERPRI SES

COUNCIL

Eu

ropaB

io

FORO DE I+D BIOMEDICA GLOBAL

LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA: CHINA, SINGAPUR Y COREA DEL SUR

STRENGHTS, CHALLENGES AND DRIVERS OF THE CHINESEBIOSCIENCES AND BIOTECH GROWTH

Carlos Martinez-A

Medicines are medicinesMedicines are medicines

Corn is cornCorn is cornSoya is soyaSoya is soya

BioPlastic is plasticBioPlastic is plasticBioDiesel is diesel.BioDiesel is diesel.

Communicating biotech ....


COUNCIL

Eu

ropaB

io

European Biotech Industry

?

Pre-seed Seed VC IPO Follow on

Debt

Here? Here? Here? Here? Here? Here?

Or along the capital pipeline?


COUNCIL

Eu

ropaB

io


• Fragmentation lack of critical mass:

– Product markets

– Financial markets

– Regulatory frameworks

– Centers of excellence and clusters

• Business attitude

• Political attitude

• “10-year gap”

• Lack of all forms of finance


COUNCIL

Eu

ropaB

io


In 2004 Europe Ratio US

Number of companies 2,150 1:1 1,991

Number of employees 96,500 1:2 190,500

R&D expenditure €7.6 billion 1:3 €21 billion

Revenue €21.5 billion 1:2 €41.5 billion

Number of products in clinical development (in 2003)

450 compounds 1:2 1,110 compounds

Source: Critical I and EuropaBio


COUNCIL

Eu

ropaB

io


In 2004 Europe Ratio US

Venture Capital €1.1 billion 1:2.5 €2.5 billion

Equity funding (IPO/2nd) €2.1 billion 1:4.5 €9.6 billion

Average VC funding per company (overall high-tech)

€1.2 million 1:5 €6 million

Number of listed companies 106 1:3 344

Market Caps (i.e. equity value of listed companies)

€19 billion 1:9 €175 billion

Source: Critical I and EuropaBio


COUNCIL

Eu

ropaB

io


… less products in development

Products in clinical development: 450 1,110

Lower R&D budgets in Europe, means…

0

2

4

6

8

10

12

0 to 2 3 to 5 6 to 10 11 to 15

Years

R&

D B

ud

get

(E

UR

mill

ion

)

Europe

US


COUNCIL

Eu

ropaB

io

Fuente: Ernst & Young, Beyond Borders (Biotech Report), Nov 2005

La productividad de las biotech es superior a la de las farmacéuticas

European Biotech Productivity


COUNCIL

Eu

ropaB

io

Durante el 2005 las compañías de biotecnología han experimentado una rentabilidad superior a las Farmacéuticas y a los principales índices

Fuente: Bloomberg, Abn Amro



COUNCIL

Eu

ropaB

io


… En su conjunto el valor de capitalización bursátil del sector es igual al valor bursátil de Pfizer y GSK …. con 8 veces el potencial de crecimiento

Fuente: GS Global research 2003, SG Cowen Pipeline Plus March 2004, BB Biotech

Pfizer y Glaxosmithkline World Biotech Sector

Valor de capitalización bursátil (miles de millones de dólares)

334,9343,3

Pfizer y Glaxosmithkline World Biotech Sector

958

Programas en fase clínica (Numero de programas)

110

Fase I

Fase II/IIIFase I

Fase II/III



COUNCIL

Eu

ropaB

io


VALUE

RISK

R&D risks

IP risks

Financing risks

Regulatory risks

Market risks

Political risks

TIME


COUNCIL

Eu

ropaB

io


VALUE

RISK

R&D risks

IP risks

Financing risks

Regulatory risks

Market risks

Political risks

Political support

TIME


COUNCIL

Eu

ropaB

io

The Spanish Government has presented the INGENIO 2010 program to stimulate R&D+i

Reach 2% of the GDP for R&D in 2010 and 1.5% in 2007 Reach 55% private contribution in R&D investment in 2010 Achieve the EU mean in the percentage of the GDP assigned for

TIC, to go from 4.8% in 2004 to 7% in 2010

OBJECTIVES

INSTRUMENTS

CENIT: public-private collaboration• CENIT projects• Fund of Capital Risk funds • “Torres Quevedo” Program• Increased the number of spin-offs by four folds

CONSOLIDER: increase critical mass and researcher excellence

Avanz@: convergence of the EU with the Information Society

Ingenio 2010

Budget ≈ 8.000 M€


COUNCIL

Eu

ropaB

io

1907: Council for the Extension of Studies and Scientific Research

CSIC: over 60 years devoted to R&DCSIC: over 60 years devoted to R&D

Santiago Ramón y CajalThe Nobel Prize in Physiology or Medicine 1906

Severo OchoaThe Nobel Prize in Physiology or Medicine 1959


COUNCIL

Eu

ropaB

io

CSIC: over 60 years devoted to R&DCSIC: over 60 years devoted to R&D

PerformingPerforming: – Multidisciplinary Scientific and Technological Research– Scientific and Technical Assessments– Training of scientific and technical personnel– Management of infrastructures

11

CATALUÑA

BALEARES

ARAGON

NAVARRA

ASTURIAS

CASTILLA-LEON

CASTILLA-LA MANCHA

MADRID

GALICIA

EXTREMADURA

ANDALUCIA

MURCIA

C. VALENCIANA

13+[4]+(3)

3+[3]

[1]

[1]

[2]

[1]

[1]3+[7]

33+[7]+(5)

1

13+[7]+(1)

2+[3]

1+[1]

23+[1]

ROMA

1

CANTABRIA PAIS VASCO Organised:Organised:

– Network of 116 Institutes (including 40 joint Centres with other Institutions)– 134 Associated Units

Collaborating with: Collaborating with: – Universities– Other public R&D Organisations– Industries– Enterprises, Professional Associations and Foundations– Regional Governments


COUNCIL

Eu

ropaB

io

Budget & Human ResourcesBudget & Human Resources

MEC

External resources

TOTAL BUDGET: 530 M€

38,5 %

61,5 %

BUDGET

2.400 Research Staff

4.000 Postgraduate students and Postdocs

4.000 Administrative and Technicians

2.400 Research Staff

4.000 Postgraduate students and Postdocs

4.000 Administrative and Technicians

HUMAN RESOURCES

TOTAL : 10.400

TOTAL: 204 M€

REGIONALGOVERNMENTS

NATIONAL RESEARCH

PLAN OF R&D

EU

INDUSTRY

OTHERS7,9%

40,7%

16,%

18,%15,%


COUNCIL

Eu

ropaB

io

Andalusian Center of Developmental Biology. CABD, SevillaAndalusian Center of Molecular Biology and Regenerative Medicine. CABIMER, SevillaCenter of Cardiovascular Research. CIC, BarcelonaCenter for Regenerative Medicine, CMR, BarcelonaCenter of Biological Research. CIB, MadridNational Center of Biotechnology. CNB, MadridInstitute of Molecular and Cellular Biology “Primo Yúfera”. IBMCP, ValenciaInstitute of Molecular and Cellular Biology of Cancer. IBMCC, SalamancaInstitute of Molecular Biology of Barcelona. IBMB, BarcelonaLaboratory of Plant Genetics-IBMB. BarcelonaCenter of Molecular Biology, CBM, MadridInstitute of Biology and Molecular Genetics. IBGM, ValladolidInstitute of Biomedicine of Valencia. IBV, ValenciaInstitute of Plant Biology and Photosynthesis. IBVF, SevillaInstitute of Biomedical Research “Alberto Sols”. IIB, MadridInstitute of Biomedical Research of Barcelona. IIBB, BarcelonaInstitute of Biochemical Microbiology. IMB, SalamancaInstitute of Neurobiology “Ramón y Cajal”. INRC, SalamancaInstitute of Neurosciences of Alicante. INA, AlicanteInstitute of Parasitology and Biomedicine “López Neyra”. IPBLN, GranadaUnit of Biophysics. UBF, Bilbao

CSIC Institutes in the Scientific Area of Biology and Biomedicine

CSIC Institutes in the Scientific Area of Biology and Biomedicine

21 R

esea

rch

Cen

ters


COUNCIL

Eu

ropaB

io

REC

UR

SOS

ECO

NÓ

MIC

OS


COUNCIL

Eu

ropaB

io

0

2

4

6

8

10

12

1999 2000 2001 2002 2003 2004 2005

Núm

ero E

BT

.

0

5

10

15

20

25

30

35

40

45

50

Núm

ero A

cum

ula

do E

BT

.

Numero de EBT Numero Acumulado de EBT

KNOWLEDGE TRANSFER

EMPR

ESA

S D

E B

ASE

TEC

NO

LÓG

ICA

EMPR

ESA

S D

E B

ASE

TEC

NO

LÓG

ICA


COUNCIL

Eu

ropaB

io

CSIC’s Subscribed Agreements

CSIC – Asia CollaborationCSIC – Asia Collaboration

CHINAChinese Academy of Sciences (CAS)National Natural Science Foundation (NSFC)

Republic of KOREAKorea Science and Engineering Foundation (KOSEF)

JAPANJapan Society for the Promotion of Science (JSPS)

TAIWANNational Science Council (NSC)

VIETNAMVietnamese Academy of Science and Technology (VAST)

Joint projects and

exchange of researchers

Bottom-up approach


COUNCIL

Eu

ropaB

io

Thank you!

Gracias!

Documents

FORO DE I+D BIOMEDICA GLOBAL LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA: CHINA, SINGAPUR Y COREA DEL SUR STRENGHTS, CHALLENGES AND DRIVERS OF THE CHINESE